What 4 Analyst Ratings Have To Say About Mersana Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Mersana Therapeutics (NASDAQ:MRSN) stock, with 3 bullish and 1 indifferent. The company has an average 12-month price target of $11.0, down 13.18% from the previous average of $12.67.
June 16, 2023 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mersana Therapeutics (MRSN) has received 3 bullish and 1 indifferent ratings from 4 analysts in the past 3 months. The average 12-month price target is $11.0, down 13.18% from the previous average.
The majority of analysts have a bullish outlook on Mersana Therapeutics, which is likely to have a positive impact on the stock price in the short term. The decrease in the average price target, however, may indicate some caution among analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100